BIG trials to be highlighted at ASCO 2017
- The phase III APHINITY study, which is part of ASCO’s official press programme on Monday 5 June, will be presenting detailed results. This trial is testing whether adding a drug called pertuzumab to the standard adjuvant treatment (trastuzumab and chemotherapy) in patients with operable HER2-positive primary breast cancer improves the outcome of patients with the disease.
An initial announcement was made in March 2017, which stated that Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy.
(Abstract LBA500)
- On Sunday 4 June, Dr Fatima Cardoso will be presenting a poster on Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer : Results from the chemotherapy randomisation (R-C) of the MINDACT phase III trial.
(Poster Board #116) (Abstract 516)
- The phase III ALTTO trial, a randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer, will have updated results presented at an oral abstract session on Monday 5 June.
(Abstract 502)
- Dr Jens Bodo Huober will be presenting, on Sunday 4 June, a poster with updated results of survival outcomes for NeoALTTO, the Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Organisation study is a randomised, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.
(Board 112) (Abstract 512)